查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
2022-2029 年全球干细胞库市场
市场调查报告书
商品编码
1153816

2022-2029 年全球干细胞库市场

Global Stem Cell Banking Market - 2022-2029
出版日期: | 出版商: DataM Intelligence | 英文 200 Pages | 商品交期: 约2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

简介目录

市场概览

全球干细胞银行市场在 2021 年将达到 50.1563 亿美元，到 2029 年将达到 159.4792 亿美元，在预测期内 (2022-2029) 的复合年增长率为 15.68%，预计将在

干细胞是未分化的细胞，可以通过细胞分裂无限地自我更新。此外，这些细胞可以分化成具有特定功能的更成熟的细胞。干细胞现在用于治疗 80 多种令人头疼的疾病。干细胞库收集、提取和冷冻保存干细胞和其他免疫系统细胞，以供未来潜在的医疗用途。

市场动态

人们对干细胞治疗潜力的认识不断提高，这推动了对这些诊断产品的需求不断增加。此外，新技术的进步和研发费用的增加也是推动市场增长的因素。所有这些因素都有望推动市场增长。

越来越多的新产品发布和不断增加的研发将推动市场增长。

干细胞库的全球市场主要是由人们对干细胞治疗潜力的认识不断提高所推动的。推动市场增长的其他因素包括新型干细胞储存、加工和保存技术的进步。增加造血干细胞移植和增加对基于干细胞的研究的投资将进一步推动干细胞库。新兴经济体、全球主要疾病负担的增加、高出生率、GDP 增长和可支配收入的增长为主要参与者提供了市场机会。例如，2021 年 9 月，干细胞库和诊断解决方案提供商 LifeCell 宣布其新疗法 Mesocel 将获得印度 DGCI（药物管制总局）治疗 COVID-19 的临床试验批准。宣布已收购Mesocel 来源于从捐赠的脐带组织中获得的间充质干细胞。这使得能够治疗患有危及生命的 COVID-19 肺炎和急性呼吸窘迫的患者。临床试验将分两个阶段进行。

越来越多的融资轮次、新技术进步和最新的创新产品发布导致对这些干细胞库的高需求。例如，2021 年 3 月，干细胞银行 LifeCell 推出了 StemMatch，这是银行会员社区的首创服务，可提供有关可在 LifeCell 註册表中匹配的干细胞单位的确切质量和数量的信息。

干细胞库的高处理和运营成本阻碍了市场增长。

然而，干细胞库的高运营成本、干细胞采集过程中的法律和伦理问题、严格的监管框架以及低接受度和认可度可能会阻碍市场的进步。这些干细胞疗法的高成本阻碍了市场增长。据干细胞治疗创新诊所 DVC Stem 称，其 IRB 批准的间充质干细胞 (MSC) 方案预计成本约为 25,000 美元。

COVID-19 影响分析

疫情对全球金融预期、运营和危机应对策略产生了负面影响。 COVID-19 疫情对医疗保健行业产生了严重影响。由于 COVID 的关注，所有研究和临床试验都受到影响，干细胞银行市场遭受了巨大损失。但现在，市场进入者正在改变他们的长期和短期增长战略，利用研究市场和创造尖端项目来对抗这一流行病。世界各地正在发生各种倡议、合作和合併，促进了市场的增长。例如，2022 年 8 月，脐带血再生疗法製造商 StemCyte 宣布获得美国食品和药物管理局的批准，可以使用脐带血干细胞疗法对 COVID 后综合征进行 2 期临床试验。

内容

第 1 章市场研究方法和范围

  • 调查方法
  • 调查目的和范围

第 2 章市场定义和概述

第 3 章执行摘要

第四章市场动态

  • 市场影响因素
    • 司机
      • 新产品发布次数增加
      • 增加研发
    • 约束因素
      • 与干细胞疗法相关的高费用
    • 商机
    • 影响分析

第五章行业分析

  • 搬运工的五种力量
  • 未满足的需求
  • 供应链分析
  • 监管分析

第 6 章 COVID-19 分析

  • COVID-19 市场分析
    • COVID-19 之前的市场情景
    • COVID-19 的当前市场情景
    • COVID-19 后或未来情景
  • COVID-19 期间的价格动态
  • 供需范围
  • 大流行期间与市场相关的政府举措
  • 製造商的战略举措
  • 总结

第 7 章出处

  • 脐带来源的干细胞 (UCSC)
  • 胎盘干细胞 (PSC)
  • 脂肪组织来源的干细胞 (ADSC)
  • 骨髓来源的干细胞 (BMSC)
  • 人类胚胎干细胞 (HESC)
  • 其他干细胞来源

第 8 章按服务类型

  • 保存/储存
  • 处理中
  • 收集和运输
  • 分析

第9章银行类型

  • 公共机构
  • 私人

第 10 章应用

  • 脑瘫
  • 白血病
  • 地中海贫血
  • 糖尿病
  • 自闭症
  • 其他

第11章按地区

  • 北美
    • 美国
    • 加拿大
    • 墨西哥
  • 欧洲
    • 德国
    • 英国
    • 法国
    • 意大利
    • 西班牙
    • 其他欧洲
  • 南美洲
    • 巴西
    • 阿根廷
    • 其他南美洲
  • 亚太地区
    • 中国
    • 印度
    • 日本
    • 澳大利亚
    • 其他亚太地区
  • 中东和非洲

第12章竞争格局

  • 主要发展和战略
  • 公司股票分析
  • 产品基准
  • 值得关注的主要公司名单

第13章公司简介

  • Stem Cyte, Inc.
    • 公司简介
    • 产品组合和说明
    • 主要亮点
    • 财务摘要
  • Cryo-cell International
  • American CryoStem Corporation
  • ViaCord
  • Cord Blood Registry Systems
  • SmartCells, Inc.（Merck）
  • LifeCell International Pvt. Ltd.
  • Cryoviva Biotech Pvt. Ltd
  • Cordlife Group Ltd.
  • Transcell Biolife Pvt. Ltd.

第14章 全球干细胞库市场-DataM

简介目录
Product Code: DMBT860

Market Overview

The global stem cell banking market was valued at US$ 5,015.63 million in 2021 and is estimated to reach US$ 15,947.92 million by 2029, growing at a CAGR of 15.68% during the forecast period (2022-2029).

Stem cells are undifferentiated cells that can self-renew indefinitely through cell division. These cells can also be distinguished into more mature cells with specific functions. Currently, stem cells are used to treat more than 80 nasty diseases. Stem cell banking is collecting, extracting and storing by cryogenically freezing the stem cells and other immune system cells for potential future medical use.

Market Dynamics

The increasing demand for these diagnostic products is due to the growing awareness of the therapeutic potential of stem cells. Other factors aiding the market growth are the advancements in novel technologies and increasing research and development expenditure. All these factors are expected to drive market growth.

The increasing number of novel product launches and the rising research and development will drive market growth.

The global market for stem cell banking is primarily driven by the growing awareness of the therapeutic potential of stem cells. Other factors aiding the market growth are advancements in novel stem cell preservation, processing, and storage technologies. The rise in hematopoietic stem cell transplantation procedures and increasing investments in stem cell-based research further propel stem cell banking. Emerging countries, the rising global burden of major diseases, the large number of newborns, the growth in GDP growth, and disposable income act as market opportunities for key players. For instance, in Sep 2021, LifeCell, a stem cell bank and provider of diagnostic solutions, announced that its novel therapy, Mesocel, got approved for a clinical trial from DGCI, the Drug Controller General of India, for COVID-19 treatment. Mesocel is extracted from mesenchymal stem cells derived from the donated umbilical cord tissue. This can now be used to treat patients with life-threatening COVID-19 pneumonia or acute respiratory distress. The clinical trial will be conducted in 2 phases.

Various funding, novel technological advancements, and the number of the latest, innovative product launches are increasing, leading to the high demand for these stem cell banking. For instance, in Mar 2021, LifeCell, a stem cell banking company, launched StemMatch, a first-of-its-kind service for the banking members community as it gives information on the accurate quality and number of stem cell units that are matching available within the LifeCell registry.

The high therapy and operational costs associated with stem cell banking will hamper the market's growth.

However, the high operational costs of stem cell banking and legal and ethical issues during the collection of stem cells, along with stringent regulatory frameworks and lack of acceptance and awareness, may hinder the market progress. The high cost of these stem cell therapies is hindering the market growth. According to DVC Stem, an innovative clinic of stem cell therapy, its mesenchymal stem cell (MSC) protocol that is IRB approved costs around US$25,000.

COVID-19 Impact Analysis

The pandemic has negatively impacted global financial expectations, operations and crisis response strategy. The COVID-19 outbreak has severely impacted the healthcare industry. The stem cell banking market has experienced huge losses due to COVID, as all the research and clinical trials got affected due to the diversion of attention toward COVID. But now, the market participants are changing their long-term and short-term growth strategies by utilizing the research market and creating cutting-edge items to combat the pandemic. Various initiatives, collaborations and mergers are happening worldwide, boosting the market's growth. For instance, in Aug 2022, StemCyte, a company manufacturing cord blood regenerative therapeutic, announced that Post-COVID Syndrome's Phase II clinical trial with the help of umbilical cord blood stem cell therapy got approved by U.S. Food and Drug Administration.

Segment Analysis

The umbilical cord-derived stem cells segment is expected to grow at the fastest CAGR during the forecast period (2022-2029)

The umbilical cord-derived stem cells (UCSTs) segment is the highest market holder in the global stem cell banking market. Cord Blood is affluent in stem cells. Stem cells are developed in the bone marrow and differentiate into different blood cells, which are important in various therapies related to blood disorders, such as sickle cell disease. Umbilical cord blood can be used for gene therapy or transplantation as it's a hematopoietic stem cell source. Umbilical cord-derived mesenchymal stem cells can be used for inflammatory and immune disease therapy. These can be promising active substances for therapeutic product development as they have a few issues related to safety, availability and ethics.

Umbilical cord-derived stem cells dominate the market due to the rising birth rate and global chronic disease cases. According to the Centre for Disease Control and Prevention, in 2021, approximately 3,659,289 newborn cases were reported in the United States. The rising number of people suffering from blood-related disorders, regulatory approvals and growing technological advancements or research/clinical trial studies drive the market's growth. For instance, in May 2021, Cordlife Group Limited, 1st private cord blood bank in Singapore, entered into a partnership with SingHealth Duke-NUS Academic Medical Centre to test new technology that can increase blood-forming stem cells in number from stored umbilical cord blood that is stored in the first-in-man study in Singapore.

Geographical Analysis

North America holds the largest market share of the global stem cell banking market.

North America dominates the global stem cell banking market, primarily attributed to the rising prevalence of chronic ailments such as leukemia, thalassemia, diabetes, autism and many more due to changing environments worldwide, established healthcare infrastructure, and higher investment in R&D activities contribute to North America's rapid share growth. Moreover, its broad base patient population also contributes to the growth of its share. According to the American Cancer Society, in 2022, Around 60.650 estimated novel leukemia cases will occur, out of which 24,000 deaths will occur in the United States.

Moreover, the growing number of product launches is responsible for the market's growth. Other factors, such as the high spending of GDP on healthcare, stimulate the market's growth. Many key developments, technological advancements, collaborations and agreements are taking place in this region. For instance, in Feb 2021, American CryoStem Corporation, a biotechnology company at the clinical stage working on autologous cellular therapies, announced its agreement with BioTherapeutics Labs Corp., a company manufacturing umbilical cord tissues that's also FDA-registered.

Competitive Landscape

The stem cell banking market is highly competitive with local and global companies' presence. Stem Cyte Inc., Cryo-cell International, American CryoStem Corporation, ViaCord, Cord Blood Registry Systems, SmartCells, Inc. (Merck), LifeCell International Pvt. Ltd., Cryoviva Biotech Pvt. Ltd, Cordlife Group Ltd., Transcell Biolife Pvt. Ltd and more. The key players are adopting various growth strategies such as product launches, mergers & acquisitions, partnerships, and collaborations, contributing to the market's growth. For instance, in Feb 2021, Cryo-Cell International Inc, a private cord blood bank that separates and stores stem cells, announced a collaboration with Duke University. With this agreement, Cryo-Cell gets the rights to regulatory data and proprietary processes developed at Duke related to cord tissue or blood.

StemCyte:

Overview:

StemCyte Inc. is a company involved in blood regenerative therapeutics. It provides family storage and public donations and is the only for-profit company that the US Department of HHS contracts. It was established in 1997 and is headquartered in California, United States.

Product Portfolio:

MaxCell: MaxCell is StemCyte's proprietary processing method that retains the stem cells in higher volume. It preserves more total nucleated cells than other standard processing procedures, improving engraftment chances.

Key Development: In May 2022, StemCyte, a blood regenerative therapeutics company, announced renewing its agreement with California Umbilical Cord Blood Collection Program. StemCyte helped raise collections at hospitals in Southern California by extending the cord blood collection hours.

The global stem cell banking market report would provide access to approximately 40+ market data tables, 45+ figures, and 200 (approximate) pages.

Table of Contents

1. Market Methodology and Scope

  • 1.1. Research Methodology
  • 1.2. Research Objective and Scope of the Report

2. Market Definition and Overview

3. Executive Summary

4. Market Dynamics

  • 4.1. Market Impacting Factors
    • 4.1.1. Drivers
      • 4.1.1.1. The rising novel product launches
      • 4.1.1.2. Increasing research and development
    • 4.1.2. Restraints:
      • 4.1.2.1. High cost associated with stem cell therapies
    • 4.1.3. Opportunity
    • 4.1.4. Impact Analysis

5. Industry Analysis

  • 5.1. Porter's Five Forces
  • 5.2. Unmet Needs
  • 5.3. Supply chain Analysis
  • 5.4. Regulatory Analysis

6. COVID-19 Analysis

  • 6.1. Analysis of Covid-19 on the Market
    • 6.1.1. Before COVID-19 Market Scenario
    • 6.1.2. Present COVID-19 Market Scenario
    • 6.1.3. After COVID-19 or Future Scenario
  • 6.2. Pricing Dynamics Amid Covid-19
  • 6.3. Demand-Supply Spectrum
  • 6.4. Government Initiatives Related to the Market During the Pandemic
  • 6.5. Manufacturer's Strategic Initiatives
  • 6.6. Conclusion

7. By Source

  • 7.1. Introduction
    • 7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Source
    • 7.1.2. Market Attractiveness Index, By Source
  • 7.2. Umbilical Cord-Derived Stem Cells (UCSCs)*
    • 7.2.1. Introduction
    • 7.2.2. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
  • 7.3. Placental Stem Cells (PSCs)
  • 7.4. Adipose Tissue-Derived Stem Cells (ADSCs)
  • 7.5. Bone Marrow-Derived Stem Cells (BMSCs)
  • 7.6. Human Embryo-Derived Stem Cells (HESCs)
  • 7.7. Other Stem Cell Sources

8. By Service Type

  • 8.1. Introduction
    • 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Service Type
    • 8.1.2. Market Attractiveness Index, By Service Type
  • 8.2. Preservation and Storage*
    • 8.2.1. Introduction
    • 8.2.2. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
  • 8.3. Processing
  • 8.4. Collection and Transportation
  • 8.5. Analysis

9. By Type of Banking

  • 9.1. Introduction
    • 9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type of Banking
    • 9.1.2. Market Attractiveness Index, By Type of Banking
  • 9.2. Public *
    • 9.2.1. Introduction
    • 9.2.2. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
  • 9.3. Private

10. By Application

  • 10.1. Introduction
    • 10.1.1. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029, By Application
    • 10.1.2. Market Attractiveness Index, By Application
  • 10.2. Cerebral Palsy *
    • 10.2.1. Introduction
    • 10.2.2. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
  • 10.3. Leukemia
  • 10.4. Thalassemia
  • 10.5. Diabetes
  • 10.6. Autism
  • 10.7. Others

11. By Region

  • 11.1. Introduction
    • 11.1.1. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029, By Region
    • 11.1.2. Market Attractiveness Index, By Region
  • 11.2. North America
    • 11.2.1. Introduction
    • 11.2.2. Key Region-Specific Dynamics
    • 11.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Source
    • 11.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Service Type
    • 11.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type of Banking
    • 11.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), Application
    • 11.2.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 11.2.7.1. The U.S.
      • 11.2.7.2. Canada
      • 11.2.7.3. Mexico
  • 11.3. Europe
    • 11.3.1. Introduction
    • 11.3.2. Key Region-Specific Dynamics
    • 11.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Source
    • 11.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Service Type
    • 11.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type of Banking
    • 11.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), Application
    • 11.3.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 11.3.7.1. Germany
      • 11.3.7.2. The U.K.
      • 11.3.7.3. France
      • 11.3.7.4. Italy
      • 11.3.7.5. Spain
      • 11.3.7.6. Rest of Europe
  • 11.4. South America
    • 11.4.1. Introduction
    • 11.4.2. Key Region-Specific Dynamics
    • 11.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Source
    • 11.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Service Type
    • 11.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type of Banking
    • 11.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), Application
    • 11.4.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 11.4.7.1. Brazil
      • 11.4.7.2. Argentina
      • 11.4.7.3. Rest of South America
  • 11.5. Asia Pacific
    • 11.5.1. Introduction
    • 11.5.2. Key Region-Specific Dynamics
    • 11.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Source
    • 11.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Service Type
    • 11.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type of Banking
    • 11.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), Application
    • 11.5.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 11.5.7.1. China
      • 11.5.7.2. India
      • 11.5.7.3. Japan
      • 11.5.7.4. Australia
      • 11.5.7.5. Rest of Asia Pacific
  • 11.6. Middle East and Africa
    • 11.6.1. Introduction
    • 11.6.2. Key Region-Specific Dynamics
    • 11.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Source
    • 11.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Service Type
    • 11.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type of Banking
    • 11.6.6. Market Size Analysis and Y-o-Y Growth Analysis (%), Application
    • 11.6.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country

12. Competitive Landscape

  • 12.1. Key Developments and Strategies
  • 12.2. Company Share Analysis
  • 12.3. Product Benchmarking
  • 12.4. List of Key Companies to Watch

13. Company Profiles

  • 13.1. Stem Cyte, Inc.
    • 13.1.1. Company Overview
    • 13.1.2. Product Portfolio and Description
    • 13.1.3. Key Highlights
    • 13.1.4. Financial Overview
  • 13.2. Cryo-cell International
  • 13.3. American CryoStem Corporation
  • 13.4. ViaCord
  • 13.5. Cord Blood Registry Systems
  • 13.6. SmartCells, Inc. (Merck)
  • 13.7. LifeCell International Pvt. Ltd.
  • 13.8. Cryoviva Biotech Pvt. Ltd
  • 13.9. Cordlife Group Ltd.
  • 13.10. Transcell Biolife Pvt. Ltd.

LIST NOT EXHAUSTIVE

14. Global Stem Cell Banking Market- DataM

  • 14.1. Appendix
  • 14.2. About Us and Services
  • 14.3. Contact Us